The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Abstract
Fibroblast growth factor 21 (FGF21) is a metabolic regulator that provides efficient and durable glycemic and lipid control in various animal models. However, its potential to treat obesity, a major health concern affecting over 30% of the population, has not been fully explored. Here we report that systemic administration of FGF21 for 2 wk in diet-induced obese and ob/ob mice lowered their mean body weight by 20% predominantly via a reduction in adiposity. Although no decrease in total caloric intake or effect on physical activity was observed, FGF21-treated animals exhibited increased energy expenditure, fat utilization, and lipid excretion, reduced hepatosteatosis, and ameliorated glycemia. Transcriptional and blood cytokine profiling studies revealed effects consistent with the ability of FGF21 to ameliorate insulin and leptin resistance, enhance fat oxidation and suppress de novo lipogenesis in liver as well as to activate futile cycling in adipose. Overall, these data suggest that FGF21 exhibits the therapeutic characteristics necessary for an effective treatment of obesity and fatty liver disease and provides novel insights into the metabolic determinants of these activities.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“prolonged administration of FGF21 or FGF21 analogues has important metabolic effects, including a marked decrease in body weight in rodents and non-human primates, and more modest effects on body weight in humans3,40,58,77,78.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [77]
In the citing paper
“Pharmacological administration of FGF21 to obese rodents reverses diabetes and obesity through increasing energy expenditure77,78.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [77]
In the citing paper
“Pharmacological administration of FGF21 decreases plasma glucose and lipid levels, improves insulin and leptin sensitivity, decreases hepatic steatosis, increases energy expenditure [[131], [132], [133], [134], [135], [136]], and decreases sugar and alcohol intake in mice [[137], [138], [139], [140], [141], [142]].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [131]
In the citing paper
“Pharmacological administration of FGF21 decreases plasma glucose and lipid levels, improves insulin and leptin sensitivity, decreases hepatic steatosis, increases energy expenditure [[131], [132], [133], [134], [135], [136]], and decreases sugar and alcohol intake in mice [[137], [138], [139], [140], [141], [142]].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [131]
In the citing paper
“Pharmacological administration of FGF21 decreases plasma glucose and lipid levels, improves insulin and leptin sensitivity, decreases hepatic steatosis, increases energy expenditure [[131], [132], [133], [134], [135], [136]], and decreases sugar and alcohol intake in mice [[137], [138], [139], [140], [141], [142]].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [131]
In the citing paper
“Pharmacological administration of FGF21 decreases plasma glucose and lipid levels, improves insulin and leptin sensitivity, decreases hepatic steatosis, increases energy expenditure [[131], [132], [133], [134], [135], [136]], and decreases sugar and alcohol intake in mice [[137], [138], [139], [140], [141], [142]].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [131]
In the citing paper
“A myriad of studies ensued demonstrating that administering FGF21 to obese or diabetic rodents and primates markedly reduced body weight and significantly improved carbohydrate and lipid homeostasis (21, 64, 65, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“When administered to diabetic and obese animal models, FGF21 provides multiple metabolic benefits and has been shown to decrease blood glucose levels and body weight, improve insulin and leptin sensitivity, improve plasma lipid profiles, and decrease hepatic steatosis (21, 64, 141, 142).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“Importantly, in animal models FGF21 treatment not only prevents (64) but also reverses diabetes and obesity (21, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“Since FGF21 administration increases energy expenditure and the browning of adipose tissues in vivo (21, 64, 141), it was hypothesized that FGF21 regulates adaptive thermogenesis in response to cold.”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“It is clear that FGF21 treatment elicits significant metabolic changes in many tissues, including the liver and adipose tissues (21, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“FGF21’s ability to reduce body weight, glucose levels, and lipid concentrations in models of obesity generated substantial initial interest”
From FGF21 and the physiological regulation of macronutrient preference (2020) · cites this paper as [116]
Citations
Cites
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
Self-citationCellular signaling by fibroblast growth factor receptors
Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,923
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young
Fajans, S. S., Bell, G. I., & Polonsky, K. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmra002168 · Cited by 1,123
Handschin, C., & Spiegelman, B. M. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0037 · Cited by 1,090
New drug targets for type 2 diabetes and the metabolic syndrome
Moller, D. E. (2001) · Nature · doi:10.1038/414821a · Cited by 1,012
Self-citationIdentification of a novel FGF, FGF-21, preferentially expressed in the liver
Nishimura, T., Nakatake, Y., Konishi, M., & Itoh, N. (2000) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(00)00067-1 · Cited by 847
Role for Stearoyl-CoA Desaturase-1 in Leptin-Mediated Weight Loss
Cohen, P., Miyazaki, M., Socci, N. D., Hagge-Greenberg, A., Liedtke, W., Soukas, A. A., Sharma, R., Hudgins, L. C., Ntambi, J. M., & Friedman, J. M. (2002) · Science · doi:10.1126/science.1071527 · Cited by 826
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 995
Glucagon Is Essential for Adaptive Thermogenesis in Brown Adipose Tissue
Kinoshita, K., Ozaki, N., Takagi, Y., Murata, Y., Oshida, Y., & Hayashi, Y. (2014) · Endocrinology · doi:10.1210/en.2014-1175 · Cited by 67
Weng, Y., Chabot, J., Bernardo, B. L., Yan, Q., Zhu, Y., Brenner, M. B., Vage, C., Logan, A., Calle, R. A., & Talukdar, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119104 · Cited by 67
Yang, M., Zhang, L., Wang, C., Liu, H., Boden, G. H., Yang, G., & Li, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048392 · Cited by 67
The Role of Fibroblast Growth Factor 21 (FGF21) on Energy Balance, Glucose and Lipid Metabolism
Ramos, D. C., Almeda‐Valdés, P., Aguilar-Salinas, C. A., Cuevas-Ramos, G., Cuevas-Sosa, A., & Gomez-Perez, F. J. (2009) · Current Diabetes Reviews · doi:10.2174/157339909789804396 · Cited by 70
Han, S.-F., Jiao, J., Zhang, W., Xu, J., Zhang, W., Chun-ling, F., & Qin, L. (2016) · Nutrition · doi:10.1016/j.nut.2016.05.006 · Cited by 69
Lees, E. K., Banks, R., Cook, C., Hill, S., Morrice, N., Grant, L., Mody, N., & Delibegović, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-10381-3 · Cited by 68
Pan, Y., Wang, B., Zheng, J., Xiong, R., Fan, Z., Ye, Y., Zhang, S., Li, Q., Gong, F., Wu, C., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14007 · Cited by 67
Phan, P., Saikia, B. B., Sonnaila, S., Agrawal, S., Alraawi, Z., Kumar, T. K. S., & Iyer, S. (2021) · Cells · doi:10.3390/cells10092418 · Cited by 70
Protein appetite as an integrator in the obesity system: the protein leverage hypothesis
Raubenheimer, D., & Simpson, S. J. (2023) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2022.0212 · Cited by 70
Palmitoleic Acid Improves Metabolic Functions in Fatty Liver by PPARα‐Dependent AMPK Activation
de Souza, C. O., Teixeira, A. A. D. S., Biondo, L. A., de Lima, E. A., Batatinha, H., & Neto, J. C. R. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25715 · Cited by 67
Role of fibroblast growth factor signalling in hepatic fibrosis
Seitz, T., & Hellerbrand, C. (2021) · Liver International · doi:10.1111/liv.14863 · Cited by 64
Andersen, B., Straarup, E. M., Heppner, K. M., Takahashi, D. L., Raffaele, V., Dissen, G. A., Lewandowski, K., Bödvarsdottir, T. B., Raun, K., Grove, K. L., et al. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0080-7 · Cited by 66
Han, S. H., Choi, S. H., Cho, B. J., Lee, Y., Lim, S. K., Park, Y. J., Moon, M. K., Lee, H. K., Kang, S., Han, D. S., et al. (2010) · Metabolism · doi:10.1016/j.metabol.2010.03.018 · Cited by 65
Kralisch, S., Tönjes, A., Krause, K., Richter, J., Lössner, U., Kovacs, P. L., Ebert, T., Blüher, M., Stümvoll, M., & Faßhauer, M. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0367 · Cited by 64
Increased FGF21 plasma levels in humans with sepsis and SIRS
Gariani, K., Drifte, G., Dunn-Siegrist, I., Pugin, J., & Jornayvaz, F. R. (2013) · Endocrine Connections · doi:10.1530/ec-13-0040 · Cited by 65
Boa, B. C. S., Yudkin, J. S., van Hinsbergh, V. W. M., Bouskela, E., & Eringa, E. C. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13732 · Cited by 65
Xu, L., Huang, D., Hu, Q., Wu, J., Wang, Y., & Feng, J. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114515002901 · Cited by 65
FGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs
Kim, K. H., & Lee, M. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0160 · Cited by 66
Metformin Stimulates FGF21 Expression in Primary Hepatocytes
Nygaard, E. B., Vienberg, S. G., Ørskov, C., Hansen, H. S., & Andersen, B. (2012) · Experimental Diabetes Research · doi:10.1155/2012/465282 · Cited by 62
Cardiac actions of fibroblast growth factor 23
Faul, C. (2016) · Bone · doi:10.1016/j.bone.2016.10.001 · Cited by 64
Host-microbiome interactions: the aryl hydrocarbon receptor and the central nervous system
Lee, H. U., McPherson, Z. E., Tan, B., Korecka, A., & Pettersson, S. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1486-0 · Cited by 65
Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues
Lin, X., Liu, Y. B., & Hu, H. (2017) · Biomedical Reports · doi:10.3892/br.2017.890 · Cited by 61
Liver-heart crosstalk controls IL-22 activity in cardiac protection after myocardial infarction
Tang, T., Li, Y.-Y., Li, J.-J., Wang, K., Han, Y., Dong, W.-Y., Zhu, Z.-F., Xia, N., Nie, S.-F., Zhang, M., et al. (2018) · Theranostics · doi:10.7150/thno.24723 · Cited by 63
Obesity medications in development
Rebello, C. J., & Greenway, F. L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1705277 · Cited by 62
Nrf2 induces fibroblast growth factor 21 in diabetic mice
Furusawa, Y., Uruno, A., Yagishita, Y., Higashi, C., & Yamamoto, M. P. (2014) · Genes to Cells · doi:10.1111/gtc.12186 · Cited by 62
A link between hepatic glucose production and peripheral energy metabolism via hepatokines
Abdul-Wahed, A., Gautier‐Stein, A., Casteras, S., Soty, M., Roussel, D., Romestaing, C., Guillou, H., Tourette, J.-A., Plèche, N., Zitoun, C., et al. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.05.005 · Cited by 75
Michalak, A., Mosińska, P., & Fichna, J. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.04.016 · Cited by 63
Role of brown adipose tissue in metabolic syndrome, aging, and cancer cachexia
Dong, M., Lin, J., Lim, W., Jin, W., & Lee, H. J. (2017) · Frontiers of Medicine · doi:10.1007/s11684-017-0555-2 · Cited by 61
Yu, Z., Lin, L., Jiang, Y., Chin, I., Wang, X., Lo, E. H., Lo, E. H., & Wang, X. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1234-2 · Cited by 62
Yano, K., Yamaguchi, K., Seko, Y., Okishio, S., Ishiba, H., Tochiki, N., Takahashi, A., Kataoka, S., Okuda, K., Liu, Y. X., et al. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00680-9 · Cited by 63
Polyethylene Glycol Modified FGF21 Engineered to Maximize Potency and Minimize Vacuole Formation
Xu, J., Bussiere, J. L., Yie, J., Sickmier, E. A., An, P., Belouski, E., Stanislaus, S., & Walker, K. W. (2013) · Bioconjugate Chemistry · doi:10.1021/bc300603k · Cited by 61
Laeger, T., Baumeier, C., Wilhelmi, I., Würfel, J., Kamitz, A., & Schürmann, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4389-x · Cited by 59
Struik, D., Dommerholt, M. B., & Jonker, J. W. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000599 · Cited by 61
FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists
Li, X., Stanislaus, S., Asuncion, F., Niu, Q.-T., Chinookoswong, N., Villasenor, K., Wang, J., Wong, P., Boyce, R., Dwyer, D., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2936 · Cited by 61
Бажан, Н. М., Jakovleva, T., Feofanova, N. A., Denisova, E. I., Dubinina, A., Sitnikova, N., & En, M. (2019) · Cells · doi:10.3390/cells8121529 · Cited by 63
Hepatic CPT1A Facilitates Liver–Adipose Cross Talk via Induction of FGF21 in Mice
Sun, W., Nie, T., Li, K., Wu, W., Long, Q., Feng, T., Mao, L., Gao, Y. Z., Liu, Q., Gao, X., et al. (2021) · Diabetes · doi:10.2337/db21-0363 · Cited by 63
Suárez, J., Rivera, P., Arrabal, S., Crespillo, A., Serrano, A., Baixerás, E., Pavón, F. J., Cifuentes, M., Nogueiras, R., Ballesteros, J., et al. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.013110 · Cited by 63
Glucagon's Metabolic Action in Health and Disease
Zeigerer, A., Sekar, R., Kleinert, M., Nason, S. R., Habegger, K. M., & Müller, T. D. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200013 · Cited by 87
Puengel, T., Lefere, S., Hundertmark, J., Kohlhepp, M., Penners, C., Van de Velde, F., Lapauw, B., Hoorens, A., Devisscher, L., Geerts, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126696 · Cited by 59
FGF21 Can Be Mimicked In Vitro and In Vivo by a Novel Anti-FGFR1c/β-Klotho Bispecific Protein
Smith, R. J., Duguay, A. N., Bakker, A., Li, P., Weiszmann, J., Thomas, M. R., Alba, B. M., Wu, X., Gupte, J., Li, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061432 · Cited by 59
Targeting the FGF19–FGFR4 pathway for cholestatic, metabolic, and cancerous diseases
Li, X., Lu, W., Kharitonenkov, A., & Luo, Y. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13767 · Cited by 64
Self-citationThe 2009 Stock Conference Report: Inflammation, Obesity and Metabolic Disease
Hevener, A. L., Febbraio, M. A., & the Stock Conference Working Group (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00691.x · Cited by 60
Amino acid transporters in the regulation of insulin secretion and signalling
Javed, K., & Fairweather, S. J. (2019) · Biochemical Society Transactions · doi:10.1042/bst20180250 · Cited by 64
Zhang, H., Zhang, W., Yun, D., Li, L., Zhao, W., Li, Y., Liu, X., & Liu, Z. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108403 · Cited by 60
Chen, M. Z., Chang, J. C., Zavala-Solorio, J., Kates, L., Thai, M., Ogasawara, A., Bai, X., Flanagan, S., Nunez, V., Phamluong, K., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.09.003 · Cited by 58
Cuevas-Ramos, D., Almeda-Valdes, P., Gómez-Pérez, F. J., Meza-Arana, C. E., Cruz-Bautista, I., Arellano-Campos, O., Navarrete-López, M., & Aguilar-Salinas, C. A. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0454 · Cited by 58
Takahashi, Y., Dungubat, E., Kusano, H., & Fukusato, T. (2023) · Biomedicines · doi:10.3390/biomedicines11102761 · Cited by 53
Choi, S. H., Hong, E. S., & Lim, S. K. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00097 · Cited by 59
Wang, Z. Q., Zhang, X. H., Yu, Y., Tipton, R. C., Raskin, I., Ribnicky, D., Johnson, W., & Cefalu, W. T. (2013) · Metabolism · doi:10.1016/j.metabol.2013.03.004 · Cited by 58
Zeng, K., Tian, L., Patel, R., Shao, W., Song, Z., Liu, L., Manuel, J., Ma, X., McGilvray, I. D., Cummins, C. L., et al. (2016) · Endocrinology · doi:10.1210/en.2016-1596 · Cited by 57
Mottillo, E. P., Desjardins, E. M., Fritzen, A. M., Zou, V. Z., Crane, J. D., Yabut, J. M., Kiens, B., Erion, D. M., Lanba, A., Granneman, J. G., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.04.001 · Cited by 57
Growth Factors as Immunotherapeutic Targets in Cardiovascular Disease
Mindur, J. E., & Świrski, F. K. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.311994 · Cited by 58
Muise, E. S., Souza, S., Chi, A., Tan, Y., Zhao, X., Liu, F., Dallas-yang, Q., Wu, M., Sarr, T., Zhu, L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073011 · Cited by 57
Wanders, D., Stone, K. P., Dille, K., Simon, J., Pierse, A., & Gettys, T. W. (2015) · BioFactors · doi:10.1002/biof.1240 · Cited by 57
Association between serum fibroblast growth factor 21 and diabetic nephropathy
Jian, W., Peng, W., Jin, J., Chen, X., Fang, W., Wang, W., Li, Q., Dong, Y., & Su, Q. (2011) · Metabolism · doi:10.1016/j.metabol.2011.10.012 · Cited by 57
Association between serum FGF21 level and sarcopenia in older adults
Jung, H.-W., Park, J. H., Kim, D. A., Jang, I.-Y., Park, S. J., Lee, J. Y., Lee, S., Kim, J. H., Yi, H.-S., Lee, E., et al. (2021) · Bone · doi:10.1016/j.bone.2021.115877 · Cited by 55
Maekawa, R., Seino, Y., Ogata, H., Murase, M., Iida, A., Hosokawa, K., Joo, E., Harada, N., Tsunekawa, S., Hamada, Y., et al. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.07.010 · Cited by 56
Aging is associated with increased FGF21 levels but unaltered FGF21 responsiveness in adipose tissue
Villarroya, J., Gallego-Escuredo, J. M., Delgado‐Anglés, A., Cairó, M., Moure, R., Mateo, M. G., Domingo, J. C., Domingo, P., Giralt, M., & Villarroya, F. (2018) · Aging Cell · doi:10.1111/acel.12822 · Cited by 56
Jiao, J., Han, S.-F., Zhang, W., Xu, J., Tong, X., Yin, X.-B., Yuan, L., & Qin, L. (2016) · Food & Nutrition Research · doi:10.3402/fnr.v60.31304 · Cited by 56
Cui, A., Li, J., Ji, S., Ma, F., Wang, G., Xue, Y., Liu, Z., Gao, J., Han, J. S., Tai, P., et al. (2020) · Diabetes · doi:10.2337/db20-0209 · Cited by 55
Fibroblast growth factor 21 (FGF21) and bone: is there a relationship in humans?
Lee, P., Linderman, J. D., Smith, S. M., Brychta, R. J., Perron, R., Idelson, C. R., Werner, C., Chen, K. Y., & Celi, F. S. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2464-9 · Cited by 55
Hormone-like fibroblast growth factors and metabolic regulation
Long, Y. C., & Kharitonenkov, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.04.002 · Cited by 55
Self-citationRole of exercise-induced hepatokines in metabolic disorders
Ennequin, G., Sirvent, P., & Whitham, M. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00433.2018 · Cited by 54
Zhang, J., Gupte, J., Gong, Y., Weiszmann, J., Zhang, Y., Lee, K. J., Richards, W. G., & Li, Y. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2016.12.016 · Cited by 54
Li, K., Li, L., Yang, M., Liu, H., Boden, G. H., & Yang, G. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.07.026 · Cited by 55
Dietary Methionine Restriction Reduces Inflammation Independent of FGF21 Action
Sharma, S., Dixon, T., Jung, S., Graff, E. C., Forney, L. A., Gettys, T. W., & Wanders, D. (2019) · Obesity · doi:10.1002/oby.22534 · Cited by 55
The Roles and Pharmacological Effects of FGF21 in Preventing Aging-Associated Metabolic Diseases
Yan, J., Nie, Y., Cao, J., Luo, M., Yan, M., Chen, Z., & He, B. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.655575 · Cited by 53
miR-21 mimic blocks obesity in mice: A novel therapeutic option
Lhamyani, S., Gentile, A., Giráldez‐Pérez, R. M., Feijoo‐Cuaresma, M., Romero‐Zerbo, S., Clemente‐Postigo, M., Zayed, H., Oliva‐Olivera, W., Bermúdez‐Silva, F. J., Salas, J., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.019 · Cited by 55
Serum FGF21 increases with hepatic fat accumulation in pediatric onset intestinal failure
Mutanen, A., Heikkilä, P., Lohi, J., Raivio, T., Jalanko, H., & Pakarinen, M. P. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.09.003 · Cited by 53
The regulation of glucose and lipid homeostasis via PLTP as a mediator of BAT–liver communication
Sponton, C. H., Hosono, T., Taura, J., Jedrychowski, M. P., Yoneshiro, T., Wang, Q., Takahashi, M., Matsui, Y., Ikeda, K., Oguri, Y., et al. (2020) · EMBO Reports · doi:10.15252/embr.201949828 · Cited by 55
Self-citationDomingo, P., Gallego-Escuredo, J. M., Domingo, J. C., Gutiérrez, M. D. M., Mateo, G. M., Fernández, I., Vidal, F., Giralt, M., & Villarroya, F. (2010) · AIDS · doi:10.1097/qad.0b013e3283400088 · Cited by 53
Ozaki, Y., Saito, K., Nakazawa, K., Konishi, M., Itoh, N., Hakuno, F., Takahashi, S.-I., Kato, H., & Takenaka, A. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114515002846 · Cited by 51
Fibroblast growth factor-21 potentiates glucose transport in skeletal muscle fibers
Rosales‐Soto, G., Díaz‐Vegas, A., Casas, M., Contreras‐Ferrat, A. E., & Jaimovich, E. (2020) · Journal of Molecular Endocrinology · doi:10.1530/jme-19-0210 · Cited by 53
FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice
Zhang, K., Gan, J., Wang, B., Lei, W., Dong, Z., Yang, J., Wang, N., Wen, C., Gao, X., Li, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56885-9 · Cited by 57
Wang, W., Li, S., Ren, G., Zheng, W., Lu, Y., Yu, Y.-H., Xu, W.-J., Li, T.-H., Zhou, L., Liu, Y., et al. (2014) · Endocrine · doi:10.1007/s12020-014-0433-5 · Cited by 52
Teng, Y., Ellis, J. M., Coleman, R., & Zeisel, S. H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.303255 · Cited by 50
Fibroblast Growth Factor 21 Suppresses Adipogenesis in Pig Intramuscular Fat Cells
Wang, Y., Liu, X., Hou, L., Wu, W., Zhao, S., & Xiong, Y. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010011 · Cited by 52
Li, Q., Zhang, Y., Ding, D., Yang, Y., Chen, Q., Su, D., Chen, X., Yang, W., Qiu, J., & Ling, W. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2308 · Cited by 52
Stengel, A., Coşkun, T., Goebel, M., Wang, L., Craft, L. S., Alsina‐Fernandez, J., Rivier, J., & Taché, Y. (2010) · Endocrinology · doi:10.1210/en.2010-0195 · Cited by 52
Wu, X., Qi, Y., Chang, J.-R., Lu, W., Zhang, J., Wang, S., Cheng, S., Zhang, M., Fan, Q., Lv, Y., et al. (2014) · Heart and Vessels · doi:10.1007/s00380-014-0557-9 · Cited by 51
Huang, Z., Wang, H., Lu, M., Sun, C., Wu, X., Tan, Y., Ye, C., Zhu, G., Wang, X., Cai, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020669 · Cited by 51
Brown Adipose Tissue: Research Milestones of a Potential Player in Human Energy Balance and Obesity
Zafrir, B. (2013) · Hormone and Metabolic Research · doi:10.1055/s-0033-1348264 · Cited by 52
Liu, X., Zhang, P., Martin, R. C. G., Cui, G., Wang, G., Tan, Y., Cai, L., Lv, G., & Li, Y. (2016) · PubMed Central · Cited by 50
Diabetes and dyslipidemia: characterizing lipoprotein metabolism
TOMKIN, G. H., & Owens, D. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s115855 · Cited by 55
Regulation of Energy Metabolism by Receptor Tyrosine Kinase Ligands
Zhao, M., Jung, Y., Jiang, Z., & Svensson, K. J. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00354 · Cited by 55
Multi-organ FGF21-FGFR1 signaling in metabolic health and disease
Kaur, N., Gare, S. R., Shen, J., Raja, R., Fonseka, O., & Liu, W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.962561 · Cited by 49
Autophagy as a crosstalk mediator of metabolic organs in regulation of energy metabolism
Kim, K. H., & Lee, M. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-013-9272-6 · Cited by 50
Kuhla, B., Kucia, M., Görs, S., Albrecht, D., Langhammer, M., Kuhla, S., & Metges, C. C. (2010) · PROTEOMICS · doi:10.1002/pmic.200900789 · Cited by 48
Thompson, W. C., Zhou, Y., Talukdar, S., & Musante, C. J. (2016) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9481-1 · Cited by 49
FGF21 induced by carbon monoxide mediates metabolic homeostasis via the PERK/ATF4 pathway
Joe, Y., Kim, S., Kim, H. J., Park, J., Chen, Y., Park, H.-J., Jekal, S., Ryter, S. W., Kim, U., & Chung, H. (2018) · The FASEB Journal · doi:10.1096/fj.201700709rr · Cited by 49
Self-citationZarei, M., Aguilar-Recarte, D., Palomer, X., & Vázquez‐Carrera, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154342 · Cited by 49
The Origins, Evolution, and Future of Dietary Methionine Restriction
Fang, H., Stone, K. P., Wanders, D., Forney, L. A., & Gettys, T. W. (2022) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062320-111849 · Cited by 47
Nonogaki, K., Hazama, M., & Satoh, N. (2014) · BioMed Research International · doi:10.1155/2014/751930 · Cited by 48
Fibroblast growth factor 21: an overview from a clinical perspective
Rydén, M. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0003-9 · Cited by 48
Bernardo, B. L., Lu, M. M., Bandyopadhyay, G. K., Li, P., Zhou, Y., Huang, J. S., Levin, N., Tomás, E., Calle, R. A., Erion, D. M., et al. (2015) · Scientific Reports · doi:10.1038/srep11382 · Cited by 49
Effects of fibroblast growth factor 21 on cell damage in vitro and atherosclerosis in vivo
Zhu, W., Wang, C., Liu, L., Li, Y., Li, X., Cai, J., & Wang, H. (2014) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2014-0227 · Cited by 48
FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats
Sa‐nguanmoo, P., Tanajak, P., Kerdphoo, S., Jaiwongkam, T., Wang, X., Liang, G., Li, X., Jiang, C., Pratchayasakul, W., Chattipakorn, N., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.12.021 · Cited by 48
Adverse bioeffect of perfluorooctanoic acid on liver metabolic function in mice
Wu, X., Xie, G., Xu, X., Wu, W., & Yang, B. (2017) · Environmental Science and Pollution Research · doi:10.1007/s11356-017-0872-7 · Cited by 48
Mu, W., Vanhoosier, E., Elks, C. M., & Grant, R. W. (2018) · Nutrients · doi:10.3390/nu10070918 · Cited by 48
Liu, D., Pang, J., Shao, W., Gu, J., Zeng, Y., He, H. H., Ling, W., Qian, X., & Jin, T. (2021) · Hepatology · doi:10.1002/hep.31856 · Cited by 48
Metadata
- Authors
- Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A.
- Affiliations
- Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285
- Eli Lilly (United States) (US)
- Corresponding author
- Kharitonenkov, Alexei
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2008-08-07
- Volume
- 149
- Issue
- 12
- Pages
- 6018-6027
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2114650931
- Cited by
- 1,031
- References
- 26
- Citations by year
- 2026: 17 · 2025: 34 · 2024: 58 · 2023: 63 · 2022: 57 · 2021: 72 · 2020: 67 · 2019: 76 · 2018: 72 · 2017: 64 · 2016: 78 · 2015: 85 · 2014: 71 · 2013: 62 · 2012: 61
- FWCI
- 12.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- FGF21, obesity, diet-induced obesity, ob/ob mice, energy expenditure, fat oxidation, de novo lipogenesis, hepatic steatosis, insulin resistance, leptin resistance, glycemia, lipid excretion, adipose tissue, metabolic therapy
- MeSH terms
- Animals, Body Weight, Energy Intake, Dietary Fats, Energy Metabolism, Fibroblast Growth Factors, Insulin, Insulin Resistance, Male, Mice, Inbred C57BL, Motor Activity, Obesity, Leptin, Adiposity, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
